{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Koehbach J"],"funding":["Centre of Excellence for Innovations in Peptide and Protein Science","Australian Research Council"],"pagination":["1249"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8228819"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["9(6)"],"pubmed_abstract":["According to the World Health Organization (WHO) the development of resistance against antibiotics by microbes is one of the most pressing health concerns. The situation will intensify since only a few pharmacological companies are currently developing novel antimicrobial compounds. Discovery and development of novel antimicrobial compounds with new modes of action are urgently needed. Antimicrobial peptides (AMPs) are known to be able to kill multidrug-resistant bacteria and, therefore, of interest to be developed into antimicrobial drugs. Proteolytic stability and toxicities of these peptides are challenges to overcome, and one strategy frequently used to address stability is cyclization. Here we introduced a disulfide-bond to cyclize a potent and nontoxic 9mer peptide and, in addition, "],"journal":["Microorganisms"],"pubmed_title":["Comparison of a Short Linear Antimicrobial Peptide with Its Disulfide-Cyclized and Cyclotide-Grafted Variants against Clinically Relevant Pathogens."],"pmcid":["PMC8228819"],"funding_grant_id":["KH001","FL150100146","CE200100012"],"pubmed_authors":["Craik DJ","Hilpert K","Koehbach J","Gani J"],"additional_accession":[]},"is_claimable":false,"name":"Comparison of a Short Linear Antimicrobial Peptide with Its Disulfide-Cyclized and Cyclotide-Grafted Variants against Clinically Relevant Pathogens.","description":"According to the World Health Organization (WHO) the development of resistance against antibiotics by microbes is one of the most pressing health concerns. The situation will intensify since only a few pharmacological companies are currently developing novel antimicrobial compounds. Discovery and development of novel antimicrobial compounds with new modes of action are urgently needed. Antimicrobial peptides (AMPs) are known to be able to kill multidrug-resistant bacteria and, therefore, of interest to be developed into antimicrobial drugs. Proteolytic stability and toxicities of these peptides are challenges to overcome, and one strategy frequently used to address stability is cyclization. Here we introduced a disulfide-bond to cyclize a potent and nontoxic 9mer peptide and, in addition, ","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Jun","modification":"2025-04-04T13:54:43.723Z","creation":"2022-02-10T19:54:27.5Z"},"accession":"S-EPMC8228819","cross_references":{"pubmed":["34201398"],"doi":["10.3390/microorganisms9061249"]}}